Filtered By:
Condition: Atrial Fibrillation
Cancer: Gastric (Stomach) Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 20 results found since Jan 2013.
Proteinuria and Risk for Heart Failure in 55,191 Patients Having History of Cancer
We examined the association of proteinuria with the risk for heart failure (HF) and other cardiovascular disease (CVD) events in patients with prior history of breast, colorectal, or stomach cancer using a nationwide population-based database.Methods: We conducted this retrospective observation study using the JMDC Claims Database and analyzed 55,191 patients with prior history of breast, colorectal, or stomach cancer. The median age was 54 (48 –60) years, and 20,665 participants (37.4%) were men. Using urine dipstick data at baseline, 3,945 and 1,521 participants were categorized as having trace and positive proteinuria...
Source: American Journal of Nephrology - December 21, 2022 Category: Neurology Source Type: research
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Anticoagulation for atrial fibrillation in active cancer
Oncol Lett. 2022 Apr;23(4):124. doi: 10.3892/ol.2022.13244. Epub 2022 Feb 17.ABSTRACTAtrial fibrillation (AF) may often pre-exist in patients with newly diagnosed cancer or occur with increased frequency shortly after cancer diagnosis. Patients with active cancer and AF have a particularly high risk of thromboembolic complications, as both conditions carry a risk of thrombosis. Thromboembolic risk is determined by several factors, including advanced age, sex (females), cancer histology (adenocarcinomas), location (e.g., pancreas, stomach), advanced stage, anticancer regimens (e.g., platinum compounds, anti-angiogenic thera...
Source: Oncology Letters - March 9, 2022 Category: Cancer & Oncology Authors: Dimitrios Farmakis Pavlos Papakotoulas Eleni Angelopoulou Theodoros Bischiniotis George Giannakoulas Panagiotis Kliridis Dimitrios Richter Ioannis Paraskevaidis Source Type: research
